Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.91 USD | +1.46% | -0.76% | +45.41% |
05-14 | Kura Oncology Enrolls 85 Patients in Ziftomenib Trial for Leukemia Drug | MT |
05-14 | Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.41% | 1.59B | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.44% | 21.25B | |
-5.52% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+37.57% | 12.54B | |
-26.24% | 8.09B |
- Stock Market
- Equities
- KURA Stock
- News Kura Oncology, Inc.
- Transcript : Kura Oncology, Inc., Q4 2021 Earnings Call, Feb 24, 2022